EpiTherapeutics ApS
Major Drugs - Copenhagen N, N/A, dk
EpiTherapeutics ApS Employees
EpiTherapeutics ApS Details
EpiTherapeutics is developing novel innovative cancer drugs based on world leading research in epigenetics.EpiTherapeutics' development programs are focused on enzymes involved in the regulation of transcription in cancer - current programs target histone demethylases and methyltransferases.The company was founded by Professor Kristian Helin and key members of his group at Biotech Research & Innovation Centre (BRIC) at University of Copenhagen.EpiTherapeutics and Abbott Laboratories started in 2011 a collaboration to develop new anti-cancer drugs by making small-molecule inhibitors against selected epigenetic oncology targets.Current investors include Novo A/S, SEED Capital Denmark, Lundbeckfond Ventures, Astellas Venture Management and Merck Serono Ventures.
EpiTherapeutics ApS Technologies
Email Providers
Outlook
Other
Microsoft Office 365